Cullinan Oncology Inc
NASDAQ:CGEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cullinan Oncology Inc
NASDAQ:CGEM
|
US |
|
ADTRAN Inc
NASDAQ:ADTN
|
US |
|
C
|
Caledonia Mining Corporation PLC
AMEX:CMCL
|
JE |
|
Hindustan Fluoro Carbons Ltd
BSE:524013
|
IN |
|
Mercan Kimya Sanayi ve Ticaret AS
IST:MERCN.E
|
TR |
|
L
|
Lpi Capital Bhd
KLSE:LPI
|
MY |
|
P
|
Parnax Lab Ltd
BSE:506128
|
IN |
|
Global Mixed Mode Technology Inc
TWSE:8081
|
TW |
Cullinan Oncology Inc
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.
